1. Home
  2. REVB vs GOVX Comparison

REVB vs GOVX Comparison

Compare REVB & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revelation Biosciences Inc.

REVB

Revelation Biosciences Inc.

HOLD

Current Price

$0.98

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.36

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REVB
GOVX
Founded
2020
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
3.8M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
REVB
GOVX
Price
$0.98
$0.36
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
25.1K
552.9K
Earning Date
05-07-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
72.68
N/A
EPS
N/A
N/A
Revenue
N/A
$2,489,145.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.12
52 Week High
$2.32
$4.40

Technical Indicators

Market Signals
Indicator
REVB
GOVX
Relative Strength Index (RSI) 49.73 N/A
Support Level $0.96 N/A
Resistance Level $1.21 N/A
Average True Range (ATR) 0.04 0.00
MACD 0.00 0.00
Stochastic Oscillator 69.23 0.00

Price Performance

Historical Comparison
REVB
GOVX

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

Share on Social Networks: